 Connection
David Raben to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications David Raben has written about Antineoplastic Combined Chemotherapy Protocols.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.696 |
|
|
|
-
Karam SD, Reddy K, Blatchford PJ, Waxweiler T, DeLouize AM, Oweida A, Somerset H, Marshall C, Young C, Davies KD, Kane M, Tan AC, Wang XJ, Jimeno A, Aisner DL, Bowles DW, Raben D. Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer. Clin Cancer Res. 2018 10 15; 24(20):4949-4959.
Score: 0.279
-
Papadimitrakopoulou VA, Frank SJ, Cohen EW, Hirsch FR, Myers JN, Heymach JV, Lin H, Tran HT, Chen CR, Jimeno A, Nedzi L, Vasselli JR, Lowe ES, Raben D. Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. Head Neck. 2016 Mar; 38(3):439-47.
Score: 0.226
-
Raben D, Bunn PA. Biologically targeted therapies plus chemotherapy plus radiotherapy in stage III non-small-cell lung cancer: a case of the Icarus syndrome? J Clin Oncol. 2012 Nov 10; 30(32):3909-12.
Score: 0.187
-
Gregoire V, Hamoir M, Chen C, Kane M, Kawecki A, Julka PK, Wang HM, Prasad S, D'Cruz AK, Radosevic-Jelic L, Kumar RR, Korzeniowski S, Fijuth J, Machiels JP, Sellers MV, Tchakov I, Raben D. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study. Radiother Oncol. 2011 Jul; 100(1):62-9.
Score: 0.173
-
Chung CH, Raben D. p16 Expression as a predictive biomarker of hypoxic cell-sensitizing agents in oropharyngeal cancer. J Clin Oncol. 2010 Sep 20; 28(27):4103-4.
Score: 0.161
-
Olsen CC, Schefter TE, Chen H, Kane M, Leong S, McCarter MD, Chen Y, Mack P, Eckhardt SG, Stiegmann G, Raben D. Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to therapy. Am J Clin Oncol. 2009 Apr; 32(2):115-21.
Score: 0.147
-
Hanna GJ, Zandberg DP, Wong DJ, Sherman E, Sacco AG, Yilmaz E, Hernando-Calvo A, Reiners RD, Bohr D, Salazar RL, O'Connell BC, Raben D, Schulten J, Chung CH, Kaczmar J. Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial. J Clin Oncol. 2026 06 20; 44(18):1697-1708.
Score: 0.120
-
Hernandez AL, Young CD, Bian L, Weigel K, Nolan K, Frederick B, Han G, He G, Devon Trahan G, Rudolph MC, Jones KL, Oweida AJ, Karam SD, Raben D, Wang XJ. PARP Inhibition Enhances Radiotherapy of SMAD4-Deficient Human Head and Neck Squamous Cell Carcinomas in Experimental Models. Clin Cancer Res. 2020 06 15; 26(12):3058-3070.
Score: 0.078
-
Stokes WA, Jones BL, Bhatia S, Oweida AJ, Bowles DW, Raben D, Goddard JA, McDermott JD, Karam SD. A comparison of overall survival for patients with T4 larynx cancer treated with surgical versus organ-preservation approaches: A National Cancer Data Base analysis. Cancer. 2017 Feb 15; 123(4):600-608.
Score: 0.062
-
Wozniak AJ, Moon J, Thomas CR, Kelly K, Mack PC, Gaspar LE, Raben D, Fitzgerald TJ, Pandya KJ, Gandara DR. A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer. 2015 Sep; 16(5):340-7.
Score: 0.055
-
Amin NP, Miften M, Kavanagh B, Raben D, Camidge DR, Thornton D, Rochford N, Gaspar LE. Impact of induction chemotherapy on estimated risk of radiation pneumonitis in small cell lung cancer. J Thorac Oncol. 2011 Sep; 6(9):1553-62.
Score: 0.043
-
Flaig TW, Su LJ, McCoach C, Li Y, Raben D, Varella-Garcia M, Bemis LT. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. BJU Int. 2009 Jun; 103(12):1729-37.
Score: 0.036
-
Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008 May 17; 371(9625):1695-709.
Score: 0.035
-
Bianco C, Giovannetti E, Ciardiello F, Mey V, Nannizzi S, Tortora G, Troiani T, Pasqualetti F, Eckhardt G, de Liguoro M, Ricciardi S, Del Tacca M, Raben D, Cionini L, Danesi R. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. Clin Cancer Res. 2006 Dec 01; 12(23):7099-107.
Score: 0.031
-
Raben D, Bianco C, Damiano V, Bianco R, Melisi D, Mignogna C, D'Armiento FP, Cionini L, Bianco AR, Tortora G, Ciardiello F, Bunn P. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. Mol Cancer Ther. 2004 Aug; 3(8):977-83.
Score: 0.027
-
Fakhry C, Zhang Q, Nguyen-Tân PF, Rosenthal DI, Weber RS, Lambert L, Trotti AM, Barrett WL, Thorstad WL, Jones CU, Yom SS, Wong SJ, Ridge JA, Rao SSD, Bonner JA, Vigneault E, Raben D, Kudrimoti MR, Harris J, Le QT, Gillison ML. Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer. J Clin Oncol. 2017 Dec 20; 35(36):4057-4065.
Score: 0.016
-
Carlson J, Licitra L, Locati L, Raben D, Persson F, Stenman G. Salivary gland cancer: an update on present and emerging therapies. Am Soc Clin Oncol Educ Book. 2013; 257-63.
Score: 0.012
-
Bradshaw-Pierce EL, Steinhauer CA, Raben D, Gustafson DL. Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma. Mol Cancer Ther. 2008 Sep; 7(9):3006-17.
Score: 0.009
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|